Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib in APDS/PASLI
NCT02593539Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemiralisib in activated phosphoinositide 3-kinase delta syndrome (APDS), sponsored by GSK. Primary endpoints: Number of Participants With Any Serious Adverse Events (SAEs) and Any Non-serious Adverse Events (Non-SAEs) up to 7.5 months, Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) at Day 84 and 7 more. Started Jul 2016; status: completed.
02
Drugs
nemiralisib
03
Conditions
activated phosphoinositide 3-kinase delta syndrome (APDS)
Beyond the preview
Go deeper on NCT02593539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593539.